Brief: Phasebio Pharmaceuticals Says Received A Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
05/07/2022 21:47
July 5 (Reuters) - PhaseBio Pharmaceuticals Inc PHAS.O :
* PHASEBIO PHARMACEUTICALS INC - ON JUNE 29, CO RECEIVED A
NOTICE
OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Source: (https://bit.ly/3aoGw6i)
Further company coverage: PHAS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PhaseBio Pharmaceuticals
See all newsBrief: Phasebio Pharmaceuticals Says Bankruptcy Court Entered Order Approving 1st Amended Combined Disclosure Statement & Chapter 11 Plan On Final Basis
U.S. RESEARCH ROUNDUP- Entegris, FedEx, Kellogg
U.S. RESEARCH ROUNDUP- Armstrong World Industries, Eli Lilly, Netflix
U.S. STOCKS ON THE MOVE-TransDigm, Vaxcyte, Tricida
PhaseBio Pharma slips on bankruptcy plans